<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39417956</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1439-0973</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>17</Day></PubDate></JournalIssue><Title>Infection</Title><ISOAbbreviation>Infection</ISOAbbreviation></Journal><ArticleTitle>Post-COVID-19-pandemic changes and clinical characteristics of invasive group a streptococcal infections from 2015 to 2023.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s15010-024-02413-8</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Since winter 2022, invasive GAS (iGAS) infections have re-emerged in Europe, causing severe diseases in children and adults. We aimed to examine whether this reported post-pandemic increase was associated with an increased disease severity and/or a shift in clinical disease phenotypes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We performed detailed clinical phenotyping of patients hospitalized with iGAS infections at a 1410-bed tertiary German Medical Center from 01/2015 to 09/2023.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">One hundred seventy-eight patients were included: 50 children (28.1%) and 128 adults (71.9%). IGAS infections of Q1/2023 exceeded the pre-pandemic average by 551% (1200% for children). The mean age of affected patients shifted significantly post-pandemically (49.5 ± 26.5 to 32.4 ± 28.2 years of age, p &lt; 0.05), mainly due to the higher percentage of children affected with iGAS infections (15.2% pre-pandemic, 44.2% post-pandemic). CFR was significantly lower for children (2%) compared to adults (11.7%) (p &lt; 0.05) and decreased from 13% to 6.5% post-pandemically (p = 0.148). Duration of antibiotic therapy (13.5 (10 to 21) to 10 (9 to 14) days), length of hospital (10 (4 to 25) to 7 (5 to 15) days), and ICU stay (7.0 (2.5 to 18.0) to 5.0 (3.0 to 8.5) days) were shorter post-pandemically. Despite the higher post-pandemic percentage of affected children, PICU admissions (57% before to 32% after), use of catecholamines (28.6% to 11.8%), invasive ventilation (35.7% to 17.6%) and CFR (7% to 0%) were all lower after the pandemic.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Children were at higher risk for iGAS infections post-pandemically. The surge of post-pandemic iGAS infections was not accompanied by increased iGAS-associated morbidity and mortality.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tomidis Chatzimanouil</LastName><ForeName>Markos K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Fetscherstraße 74, 01307, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rößler</LastName><ForeName>Susann</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute for Medical Microbiology and Virology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Infectious Diseases and Antibiotic Stewardship Unit, Carl Carus University Hospital, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nurjadi</LastName><ForeName>Dennis</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute of Medical Microbiology and Clinic for Infectious Diseases, University of Lübeck and University Medical Center Schleswig-Holstein Campus Lübeck, Lübeck, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Lübeck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iakovidis</LastName><ForeName>Isidoros</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Mathematics, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berner</LastName><ForeName>Reinhard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Fetscherstraße 74, 01307, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toepfner</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-9693-4419</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Fetscherstraße 74, 01307, Dresden, Germany. nicole.toepfner@uniklinikum-dresden.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bornstein</LastName><ForeName>The Dresden G A S Study Group Stefan Richard</ForeName><Initials>TDGASSGSR</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine III, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aschoff</LastName><ForeName>Roland</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Dermatology, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bornhäuser</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Güldner</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care Medicine, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gunzer</LastName><ForeName>Florian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute for Medical Microbiology and Virology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herold</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Trauma and Plastic Surgery, University Center of Orthopaedic, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schultz</LastName><ForeName>Jurek</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pediatric Surgery, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wimberger</LastName><ForeName>Pauline</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Gynecology and Obstetrics, Technische Universität Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zahnert</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, Head and Neck Surgery, Carl Gustav Carus Faculty of Medicine, TUD Dresden University of Technology, Dresden, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Infection</MedlineTA><NlmUniqueID>0365307</NlmUniqueID><ISSNLinking>0300-8126</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clindamycin</Keyword><Keyword MajorTopicYN="N">Invasive GAS</Keyword><Keyword MajorTopicYN="N">Sepsis</Keyword><Keyword MajorTopicYN="N">Streptococcus pyogenes</Keyword><Keyword MajorTopicYN="N">Toxic shock</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>12</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>12</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>11</Hour><Minute>19</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39417956</ArticleId><ArticleId IdType="doi">10.1007/s15010-024-02413-8</ArticleId><ArticleId IdType="pii">10.1007/s15010-024-02413-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO: Disease Outbreak News; Increased incidence of scarlet fever and invasive Group A Streptococcus infection - multi-country. https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON429 : World Health Organization 2022.</Citation></Reference><Reference><Citation>Guy R, Henderson KL, Coelho J, et al. Increase in invasive group A streptococcal infection notifications, England, 2022. Eurosurveillance. 2023;28:2200942.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2023.28.1.2200942</ArticleId><ArticleId IdType="pmc">9817207</ArticleId></ArticleIdList></Reference><Reference><Citation>de Gier B, Marchal N, de Beer-Schuurman I, et al. Increase in invasive group A streptococcal (Streptococcus pyogenes) infections (iGAS) in young children in the Netherlands, 2022. Eurosurveillance. 2023;28:2200941.</Citation><ArticleIdList><ArticleId IdType="pmc">9817208</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynskey NN, Jauneikaite E, Li HK, Zhi X, Turner CE, Mosavie M, Pearson M, Asai M, Lobkowicz L, Chow JY, Parkhill J, Lamagni T, Chalker VJ, Sriskandan S. Emergence of dominant toxigenic M1T1 Streptococcus pyogenes clone during increased scarlet fever activity in England: a population-based molecular epidemiological study. Lancet Infect Dis. 2019;19(11):1209–18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(19)30446-3</ArticleId><ArticleId IdType="pmc">6838661</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouveia C, Bajanca-Lavado MP, Mamede R, Araújo Carvalho A, Rodrigues F, Melo-Cristino J, Ramirez M, Friães A (2023); Portuguese Group for the Study of Streptococcal Infections; Portuguese Study Group of Pediatric Invasive Streptococcal Disease; Portuguese Study Group of Paediatric Invasive Streptococcal Disease. Sustained increase of paediatric invasive Streptococcus pyogenes infections dominated by M1UK and diverse emm12 isolates, Portugal, September 2022 to May 2023. Euro Surveill. 28(36):2300427</Citation></Reference><Reference><Citation>Rodriguez-Ruiz JP, Lin Q, Lammens C, Smeesters PR, van Kleef-van KS, Matheeussen V, Malhotra-Kumar S. Increase in bloodstream infections caused by emm1 group A Streptococcus correlates with emergence of toxigenic M1UK, Belgium, May 2022 to August 2023. Euro Surveill. 2023;28(36):2300422. https://doi.org/10.2807/1560-7917.ES.2023.28.36.2300422.PMID:37676145;PMCID:PMC10486196 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2023.28.36.2300422.PMID:37676145;PMCID:PMC10486196</ArticleId><ArticleId IdType="pmc">10486196</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Putten BCL, Vlaminckx BJM, de Gier B, Freudenburg-de Graaf W, van Sorge NM. Group A Streptococcal Meningitis With the M1UK Variant in the Netherlands. JAMA. 2023;329(20):1791–2. https://doi.org/10.1001/jama.2023.5927.PMID:37027150;PMCID:PMC10082416 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.5927.PMID:37027150;PMCID:PMC10082416</ArticleId><ArticleId IdType="pmc">10082416</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Rivers J, Mathis S, Li Z, Velusamy S, Nanduri SA, Van Beneden CA, Snippes-Vagnone P, Lynfield R, McGee L, Chochua S, Metcalf BJ, Beall B. Genomic Surveillance of Streptococcus pyogenes Strains Causing Invasive Disease, United States, 2016–2017. Front Microbiol. 2020;24(11):1547. https://doi.org/10.3389/fmicb.2020.01547.PMID:32849323;PMCID:PMC7396493 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2020.01547.PMID:32849323;PMCID:PMC7396493</ArticleId></ArticleIdList></Reference><Reference><Citation>Johannesen TB, Munkstrup C, Edslev SM, Baig S, Nielsen S, Funk T, Kristensen DK, Jacobsen LH, Ravn SF, Bindslev N, Gubbels S, Voldstedlund M, Jokelainen P, Hallstrøm S, Rasmussen A, Kristinsson KG, Fuglsang-Damgaard D, Dessau RB, Olsén AB, Jensen CS, Skovby A, Ellermann-Eriksen S, Jensen TG, Dzajic E, Østergaard C, Lomborg Andersen S, Hoffmann S, Andersen PH, Stegger M. Increase in invasive group A streptococcal infections and emergence of novel, rapidly expanding sub-lineage of the virulent Streptococcus pyogenes M1 clone, Denmark, 2023. Euro Surveill. 2023;28(26):2300291. https://doi.org/10.2807/1560-7917.ES.2023.28.26.2300291.PMID:37382884;PMCID:PMC10311951 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2023.28.26.2300291.PMID:37382884;PMCID:PMC10311951</ArticleId><ArticleId IdType="pmc">10311951</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo R, Sickler J, Vahidnia F, Lee YC, Frogner B, Thompson M. Diagnosis and Management of Group a Streptococcal Pharyngitis in the United States, 2011–2015. BMC Infect Dis. 2019;19(1):193. https://doi.org/10.1186/s12879-019-3835-4.PMID:30808305;PMCID:PMC6390592 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-019-3835-4.PMID:30808305;PMCID:PMC6390592</ArticleId><ArticleId IdType="pmc">6390592</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrieri P, Kaplan EL. Invasive group A streptococcal infections. Infect Dis Clin North Am. 1992;6(1):149–61 (PMID: 1578114).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0891-5520(20)30430-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Musser JM, Shelburne SA 3rd. A decade of molecular pathogenomic analysis of group A Streptococcus. J Clin Invest. 2009;119(9):2455–63. https://doi.org/10.1172/JCI38095.PMID:19729843;PMCID:PMC2735924 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI38095.PMID:19729843;PMCID:PMC2735924</ArticleId><ArticleId IdType="pmc">2735924</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunkhorst FM, Weigand MA, Pletz M, et al. S3-Leitlinie sepsis – prävention, diagnose, therapie und nachsorge. Med Klin Intensivmed Notfmed. 2020;115(Suppl 2):37–109. https://doi.org/10.1007/s00063-020-00685-0 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00063-020-00685-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss SL, Peters MJ, Alhazzani W, Agus MSD, Flori HR, Inwald DP, Nadel S, Schlapbach LJ, Tasker RC, Argent AC, Brierley J, Carcillo J, Carrol ED, Carroll CL, Cheifetz IM, Choong K, Cies JJ, Cruz AT, De Luca D, Deep A, Faust SN, De Oliveira CF, Hall MW, Ishimine P, Javouhey E, Joosten KFM, Joshi P, Karam O, Kneyber MCJ, Lemson J, MacLaren G, Mehta NM, Møller MH, Newth CJL, Nguyen TC, Nishisaki A, Nunnally ME, Parker MM, Paul RM, Randolph AG, Ranjit S, Romer LH, Scott HF, Tume LN, Verger JT, Williams EA, Wolf J, Wong HR, Zimmerman JJ, Kissoon N, Tissieres P. Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. Pediatr Crit Care Med. 2020;21(2):e52–106. https://doi.org/10.1097/PCC.0000000000002198 . (PMID: 32032273).</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0000000000002198</ArticleId></ArticleIdList></Reference><Reference><Citation>Armann J. Infektiologisches Management der Sepsis im Kindes- und Jugendalter. Intensivmedizin up2date. 2020;16(3):299–316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1019-5916</ArticleId></ArticleIdList></Reference><Reference><Citation>Miranda M, Nadel S. Pediatric sepsis: a summary of current definitions and management recommendations. Curr Pediatr Rep. 2023;11:29–39. https://doi.org/10.1007/s40124-023-00286-3 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40124-023-00286-3</ArticleId><ArticleId IdType="pmc">10169116</ArticleId></ArticleIdList></Reference><Reference><Citation>Matics TJ, Sanchez-Pinto LN. Adaptation and validation of a pediatric sequential organ failure assessment score and evaluation of the Sepsis-3 definitions in critically Ill children. JAMA Pediatr. 2017;171(10): e172352. https://doi.org/10.1001/jamapediatrics.2017.2352 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapediatrics.2017.2352</ArticleId><ArticleId IdType="pmc">6583375</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC – National Center for Health Statistics – Streptococcal Toxic Shock Syndrome. https://www.cdc.gov/groupastrep/diseases-hcp/Streptococcal-Toxic-Shock-Syndrome.html . January 7, 2024.</Citation></Reference><Reference><Citation>Hufnagel M. Sepsis und toxisches Schocksyndrom bei Kindern und Jugendlichen. In: Hoffmann G, Lentze M, Spranger J, Zepp F, Berner R, editors. Pädiatrie. Berlin: Springer Reference Medizin; 2019. p. 1–13.</Citation></Reference><Reference><Citation>Stevens LD. Invasive group A streptococcal infection and toxic shock syndrome: Epidemiology, clinical manifestations, and diagnosis. In: UpToDate, Connor RF (Ed), Wolters Kluwer. (Accessed Jan 7, 2024.)</Citation></Reference><Reference><Citation>UK Health Security Agency; Group A streptococcal infections: report on seasonal activity in England, 2022 to 2023 Updated 8 December 2022. https://www.gov.uk/government/publications/group-a-streptococcal-infections-activity-during-the-2022-to-2023-season/group-a-streptococcal-infections-report-on-seasonal-activity-in-england-2022-to-2023</Citation></Reference><Reference><Citation>Health Protection Surveillance Centre. Update on Group A streptococcus (GAS). December 7, 2022. https://www.hpsc.ie/news/newsarchive/2023newsarchive/title-22663-en.html</Citation></Reference><Reference><Citation>Santé publique France. Invasive Group A Streptococcal Infection (IISGA): update as of December 8, 2022. https://www.santepubliquefrance.fr/les-actualites/2022/infection-invasive-a-streptocoque-du-groupe-a-iisga-point-au-8-decembre-2022-et-dispositif-de-surveillance</Citation></Reference><Reference><Citation>Singer R, Abu Sin M, Tenenbaum T, Toepfner N, Berner R, Buda S, Schlaberg J, Schönfeld V, Reinacher U, van der Linden M, Claus H, Lâm TT, Schneider M, Noll I, Haller S, von Laer A. The Increase in Invasive Bacterial Infections With Respiratory Transmission in Germany, 2022/2023. Dtsch Arztebl Int. 2024;121(4):114.</Citation><ArticleIdList><ArticleId IdType="pmc">11019759</ArticleId></ArticleIdList></Reference><Reference><Citation>Efstratiou A, Lamagni T. Epidemiology of Streptococcus pyogenes. 2016 [updated 2017 Apr 3]. In: Ferretti JJ, Stevens DL, Fischetti VA, editors. Streptococcus pyogenes: Basic Biology to Clinical Manifestations [Internet]. Oklahoma City (OK): University of Oklahoma Health Sciences Center; 2016–. PMID: 26866237.</Citation></Reference><Reference><Citation>Alcolea-Medina A, Snell LB, Alder C, Charalampous T, Williams TGS; Synnovis Microbiology Laboratory Group; Tan MKI, Al-Yaakoubi N, Humayun G, Newsholme W, Goldenberg S, Nebbia G, Neil SJD, Batra R, Edgeworth JD. The ongoing Streptococcus pyogenes (Group A Streptococcus) outbreak in London United Kingdom in December 2022: a molecular epidemiology study. Clin Microbiol Infect. 2023;29(7):887–90.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2023.03.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies PJB, Russell CD, Morgan AR, Taori SK, Lindsay D, Ure R, Brown D, Smith A. Increase of severe pulmonary infections in adults caused by M1UK Streptococcus pyogenes, Central Scotland. UK Emerg Infect Dis. 2023;29(8):1638–42.</Citation></Reference><Reference><Citation>Wolters M, Berinson B, Degel-Brossmann N, Hoffmann A, Bluszis R, Aepfelbacher M, Rohde H, Christner M. Population of invasive group A streptococci isolates from a German tertiary care center is dominated by the hypertoxigenic virulent M1UK genotype. Infection. 2023;52(2):667–71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-023-02137-1</ArticleId><ArticleId IdType="pmc">10954911</ArticleId></ArticleIdList></Reference><Reference><Citation>Maldonado-Barrueco A, Bloise I, Cendejas-Bueno E, López-Rodrigo F, García-Rodríguez J, Lázaro-Perona F. Epidemiological changes in invasive Streptococcus pyogenes infection during the UK alert period: A molecular comparative analysis from a tertiary Spanish hospital in 2023. Enferm Infecc Microbiol Clin (Engl Ed). 2024;42(1):34–7. https://doi.org/10.1016/j.eimce.2023.09.003 . (PMID: 38176845).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eimce.2023.09.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Osowicki J, Nizet V. Malice in Chains. J Infect Dis. 2023;227(10):1117–8. https://doi.org/10.1093/infdis/jiad035 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiad035</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost H, Excler JL, Sriskandan S, et al. Correlates of immunity to Group A Streptococcus: a pathway to vaccine development. npj Vaccines. 2023. https://doi.org/10.1038/s41541-022-00593-8 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-022-00593-8</ArticleId><ArticleId IdType="pmc">9844947</ArticleId></ArticleIdList></Reference><Reference><Citation>Nygaard U, Hartling UB, Munkstrup C, Nielsen AB, Dungu KHS, Schmidt LS, Glenthøj J, Matthesen AT, Rytter MJH, Holm M. Invasive group A streptococcal infections in children and adolescents in Denmark during 2022–23 compared with 2016–17 to 2021–22: a nationwide, multicentre, population-based cohort study. Lancet Child Adolesc Health. 2024;8(2):112–21. https://doi.org/10.1016/S2352-4642(23)00295-X . (Epub 2023 Dec 13 PMID: 38103567).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-4642(23)00295-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Babiker A, Li X, Lai YL, Strich JR, Warner S, Sarzynski S, Dekker JP, Danner RL, Kadri SS. Effectiveness of adjunctive clindamycin in β-lactam antibiotic-treated patients with invasive β-haemolytic streptococcal infections in US hospitals: a retrospective multicentre cohort study. Lancet Infect Dis. 2021;21(5):697–710.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30523-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Linnér A, Darenberg J, Sjölin J, Henriques-Normark B, Norrby-Teglund A. Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study. Clin Infect Dis. 2014;59(6):851–7. https://doi.org/10.1093/cid/ciu449 . (Epub 2014 Jun 13 PMID: 24928291).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciu449</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreoni F, Zürcher C, Tarnutzer A, Schilcher K, Neff A, Keller N, Marques Maggio E, Poyart C, Schuepbach RA, Zinkernagel AS. Clindamycin Affects Group A Streptococcus Virulence Factors and Improves Clinical Outcome. J Infect Dis. 2017;215(2):269–77. https://doi.org/10.1093/infdis/jiw229 . (PMID: 27247345).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiw229</ArticleId></ArticleIdList></Reference><Reference><Citation>Berner, Reinhard; Bialek, Ralf; et al (2018) DGPI Handbuch, Infektionen bei Kindern und Jugendlichen, https://doi.org/10.1055/b-006-160379 , Deutsche Gesellschaft für Pädiatrische Infektiologie e.V. (DGPI); 2018 Georg Thieme Verlag KG, Georg Thieme Verlag KG, Stuttgart</Citation></Reference><Reference><Citation>Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan SL, Montoya JG, Wade JC. Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-52.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciu296</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimbelman J, Palmer A, Todd J. Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatr Infect Dis J. 1999;18(12):1096–100. https://doi.org/10.1097/00006454-199912000-00014 . (PMID: 10608632).</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00006454-199912000-00014</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortés-Penfield N, Ryder JH. Should linezolid replace clindamycin as the adjunctive antimicrobial of choice in group a streptococcal necrotizing soft tissue infection and toxic shock syndrome? A Focused Debate Clin Infect Dis. 2023;76(2):346–50. https://doi.org/10.1093/cid/ciac720 . (PMID: 36056891).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac720</ArticleId></ArticleIdList></Reference><Reference><Citation>Parks T, Wilson C, Curtis N, Norrby-Teglund A, Sriskandan S. Polyspecific intravenous immunoglobulin in clindamycin-treated patients with Streptococcal toxic shock syndrome: A systematic review and meta-analysis. Clin Infect Dis. 2018;67(9):1434–6. https://doi.org/10.1093/cid/ciy401.PMID:29788397;PMCID:PMC6186853 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciy401.PMID:29788397;PMCID:PMC6186853</ArticleId><ArticleId IdType="pmc">6186853</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>